{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:03:40Z","timestamp":1793325820223,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Aldosterone plays a critical role in maintaining volume and blood pressure control. It also plays a highly negative role in vascular diseases such as systemic hypertension, congestive heart failure, and cardiorenal syndrome due to the critical role that the renin-angiotensin-aldosterone system plays in these diseases from oxidative stress, vasoconstriction, and vascular remodeling caused by angiotensin II. Controlling aldosterone involves drugs such as angiotensin-converting enzyme inhibitor\/angiotensin receptor blockers and mineralocorticoid receptor antagonists (MRAs). Recent guidelines suggest that the MRAs were more beneficial than angiotensin-converting enzyme inhibitor\/angiotensin receptor blockers and diuretics in resistant hypertension. It is also essential to understand the role of both mineralocorticoid receptors (MRs) and glucocorticoid receptors (GRs) because they are present in many of the same tissues, and the balance of these 2 receptors is critical for homeostasis. Glucocorticoids activate MRs at basal levels and GRs at stress levels. During oxidative stress, MR activation can negatively affect the balance of MRs\/GRs interactions, cognition, and memory. The older drugs in this category were less effective than MRAs in controlling blood pressure. A new class of drugs to consider are the aldosterone synthase inhibitors, which inhibit salt and water reabsorption and decrease sympathetic stimulation. The ideal candidate drug must be capable of inhibiting the MR while sparing the glucocorticoid receptor, a challenge given the 95% homology of these receptors.<\/jats:p>","DOI":"10.1097\/crd.0000000000000838","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T14:00:31Z","timestamp":1739368831000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Aldosterone Synthase Inhibitor BI 690517: Specificity for Mineralocorticoid Receptor"],"prefix":"10.1097","author":[{"given":"Andrew M.","family":"Treihaft","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaedrea A.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"R1-20250212","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guidelines for management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R2-20250212","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1210\/clinem\/dgad071","article-title":"Aldosterone synthase inhibitors and the treatment of essential hypertension.","volume":"108","author":"Gomez-Sanchez","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-20250212","first-page":"e36184","article-title":"Aldosterone synthase inhibitors and dietary interventions: a combined novel approach for prevention and treatment of cardiovascular disease.","volume":"15","author":"Awosika","year":"2023","journal-title":"Cureus"},{"key":"R4-20250212","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1152\/physrev.00020.2012","article-title":"11\u03b2-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.","volume":"93","author":"Chapman","year":"2013","journal-title":"Physiol Rev"},{"key":"R5-20250212","doi-asserted-by":"crossref","first-page":"105332","DOI":"10.1016\/j.phrs.2020.105332","article-title":"Aldosterone synthase inhibitors for cardiovascular diseases: a comprehensive review of preclinical, clinical and in silico data.","volume":"163","author":"Lenzini","year":"2021","journal-title":"Pharmacol Res"},{"key":"R6-20250212","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"R7-20250212","doi-asserted-by":"crossref","first-page":"116521","DOI":"10.1016\/j.ejmech.2024.116521","article-title":"Emerging trends in small molecule inhibitors targeting aldosterone synthase: a new paradigm in cardiovascular disease treatment.","volume":"274","author":"Guo","year":"2024","journal-title":"Eur J Med Chem"},{"key":"R8-20250212","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review.","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"R9-20250212","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/jcm11051335","article-title":"Chronic renal failure and cardiovascular disease: a comprehensive appraisal.","volume":"11","author":"Skalsky","year":"2022","journal-title":"J Clin Med"},{"key":"R10-20250212","doi-asserted-by":"crossref","first-page":"8","DOI":"10.33696\/Pharmacol.6.048","article-title":"Aldosterone synthase inhibitors for treatment of hypertension and chronic kidney disease.","volume":"6","author":"Mikhail","year":"2024","journal-title":"Arch Pharmacol Ther"},{"key":"R11-20250212","doi-asserted-by":"crossref","first-page":"235","DOI":"10.14797\/mdcj-11-4-235","article-title":"Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure.","volume":"11","author":"Sica","year":"2015","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"R12-20250212","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000665","article-title":"Emerging therapies for treatment-resistant hyptertension: a review of lorundrostat and related selective aldosterone synthase inhbitors.","author":"Feldman","year":"2024","journal-title":"Cardiol Rev"},{"key":"R13-20250212","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"issue":"suppl_1","key":"R14-20250212","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ndt\/gft402","article-title":"Aldosterone synthase inhibitors in cardiovascular and renal diseases.","volume":"29","author":"Namsolleck","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R15-20250212","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0140-6736(23)02542-4","article-title":"Blocking aldosterone or its receptor\u2014what is the difference?","volume":"403","author":"Agarwal","year":"2024","journal-title":"Lancet"},{"key":"R16-20250212","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2147\/DDDT.S315359","article-title":"Clinical utility of osilodrostat in Cushing\u2019s disease: review of currently available literature.","volume":"17","author":"Perosevic","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"R17-20250212","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/dom.15518","article-title":"Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: a multicentre, randomized, double-blind, placebo-controlled, phase I trial.","volume":"26","author":"Bornstein","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl_1","key":"R18-20250212","first-page":"0157\u20131418","article-title":"Phase II dose-selection, randomised, controlled trial of ASi BI 690517 with and without EMPA in CKD: subgroup analysis by T2D status.","volume":"39","author":"Tuttle","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"R20-20250212","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"R21-20250212","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000534808","article-title":"Methods article for a study protocol: study design and baseline characteristics for aldosterone synthase inhibition in chronic kidney disease.","volume":"55","author":"Tuttle","year":"2024","journal-title":"Am J Nephrol"},{"key":"R23-20250212","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41440-023-01188-z","article-title":"Inhibition of aldosterone synthase: does this offer advantages compared with the blockade of mineralocorticoid receptors?","volume":"46","author":"Ando","year":"2023","journal-title":"Hypertens Res"},{"key":"R24-20250212","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes.","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T14:00:36Z","timestamp":1739368836000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000838","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}